Modality
mAb
MOA
CDK4/6i
Target
RET
Pathway
Notch
Alzheimer'sPompeMelanoma
Development Pipeline
Preclinical
~Jul 2015
→ ~Oct 2016
Phase 1
~Jan 2017
→ ~Apr 2018
Phase 2
~Jul 2018
→ ~Oct 2019
Phase 3
Jan 2020
→ Oct 2031
Phase 3Current
NCT07944052
819 pts·Alzheimer's
2020-03→2031-10·Recruiting
NCT05985713
1,760 pts·Pompe
2020-06→TBD·Completed
NCT05830210
643 pts·Melanoma
2025-07→2029-01·Active
+1 more trial
3,643 total pts3 indications
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2029-01-062.8y awayPh3 Readout· Melanoma
2031-10-075.5y awayPh3 Readout· Alzheimer's
Trial Timeline
2020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2Q3Q4
P3
Termina…
P3
Recruit…
P3
Complet…
P3
Active
Catalysts
Ph3 Readout
2029-01-06 · 2.8y away
Melanoma
Ph3 Readout
2031-10-07 · 5.5y away
Alzheimer's
RecruitingActiveCompletedTerminated|StartCompletionToday
Trials (4)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07944052 | Phase 3 | Alzheimer's | Recruiting | 819 | LiverFat |
| NCT05985713 | Phase 3 | Pompe | Completed | 1760 | DOR |
| NCT05830210 | Phase 3 | Melanoma | Active | 643 | EDSS |
| NCT05825546 | Phase 3 | Melanoma | Terminated | 421 | VA |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-5767 | Pfizer | Phase 1/2 | BET | |
| RHH-1969 | Roche | Approved | BET | |
| RHH-5389 | Roche | Preclinical | RET | |
| Fixanesiran | AbbVie | Preclinical | RET | |
| Ivocapivasertib | Bristol-Myers Squibb | Phase 1 | BET | |
| BMY-8678 | Bristol-Myers Squibb | Approved | RET | |
| Zorimavacamten | Bristol-Myers Squibb | Preclinical | Cl18.2 | |
| Fixatenlimab | GSK | Phase 1/2 | JAK1 | |
| VRT-4938 | Vertex Pharma | Preclinical | HER2 | |
| VRT-1576 | Vertex Pharma | Phase 2/3 | RET |